Dezocine is an opioid analgesic that relieves pain. Dezocine was launched in China in 2009 and has been widely used in general anesthesia induction, postoperative analgesia, and preemptive analgesia.

In the Chinese pharmaceutical market, narcotic analgesics have grown very fast in recent years, mainly due to massive surgeries in China. According to Chinese statistics, there will be more than 50 million operations in 2019, and the amount of surgeries is increasing year by year. In narcotic analgesics, Dezocine accounts for up to 60% of the market share.

According to Researcher’s market research, the sales of Dezocine had a growth trend from 2016 to 2019. The revenue in 2020 was approximately CNY2.06 billion, though it decreased by 6.18% compared to 2019 due to the COVID-19 epidemic. The CAGR of sales from 2016 to 2020 is 8.77%. Therefore, Researcher analyzes that, with the improvement of the epidemic situation, the sales of Dezocine in China are expected to have a recovery growth in 2021-2025.

Topics Covered:
-The impact of COVID-19 on China's dezocine market
- Sales value and volume of China's dezocine 2016-2020
- Competitive landscape of China's dezocine market
- Prices of dezocine in China
- Prices of dezocine in China by regions and manufacturers
- Analysis on factors affecting the development of China's dezocine market
- Prospect of China's dezocine market from 2021 to 2025